- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07270055
Swaddy, a Neonatal Positioning Device. (Swaddy)
Effect of Neonatal Device Swaddy® on the Stress Level of Preterm Newborns: A Randomized Clinical Trial.
The objective of this clinical trial is to evaluate the effect of positional restraint on the stress level of preterm newborns, resting in the incubator. The main question sought to be answered is: The stress level of the preterm newborn will decrease with swaddy® containment, compared to standard care, and both with similar safety.
Participants will remain in the incubator for 3 consecutive hours and the level of stress in the same patient will be evaluated, one day with containment and another day without containment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary objective: To assess the effect of Swaddy® containment on the stress level of newborns ≤1500 grams at birth admitted to a NICU, using the Comfort B Scale, for a maximum period of 3 consecutive hours, compared to standard containment care.
Secondary objectives:
- To evaluate the effect of positional restraint with Swaddy® on the stability of the preterm newborn, through the physiological parameters HR, RF, temperature, and SatO2, compared to standard containment care for 3 consecutive hours.
- To evaluate the safety of the number of apneas, in containment with Swaddy® compared to standard care.
Swaddy®, is an adjustable garment of clothing, with a built-in cap, which favors the symmetry of limbs with midline of the body and the hand-to-hand and hand-to-mouth position of preterm newborns, very conciliatory positions for these patients. Its fabric is thin and soft, to prevent overheating, and elastic, to favor the flexor position and allow some mobility. It is a device designed by the IP of the project, registered and patented by the Institut de Recerca Sant Pau, and currently marketed.
In this project, patients will be randomized into two groups. In Group 1, on the first day (day 1), the first measurement (baseline) will be made. Subsequently, the Swaddy® containment device will be placed and the containment will be maintained for 3 hours, in which the same variables will be measured: Heart Rate (HR), Respiratory Rate (RF), temperature, O2 Saturation (SatO2) and pain scale at 60, 120 and 180 minutes. This procedure will be repeated on day 2 and 3. On day 4, the same measurements will be carried out using standard containment care. This procedure will be repeated on days 5 and 6 (all three at approximately the same time of day as in the intervention). In Group 2, it will be done in reverse.
Vital signs HR, RF, oxygen saturation will be measured with the patient's monitor and temperature with a skin sensor in the incubator itself, which will be located in the patient's thoracoabdominal area.
To assess the safety of the device, the number of apneas of prematurity performed with Swaddy® containment and standard care will be recorded.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Silvia VICENTE PÉREZ, Principal Investigator
- Phone Number: +34 647531247
- Email: svicente@santpau.cat
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Newborns weighing ≤1500 grams at birth admitted to the NICU. • Patients who are in an incubator.
Exclusion Criteria:
Hemodynamic instability.
- Be a carrier of CPAP or nasal BIPAP with a cap (because the CPAP/BIPAP already has a built-in cap, just like Swaddy).
- Be in treatment with phototherapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Group Swaddy first
In this project, patients will be randomized into two groups.
In Group 1, on the first day (day 1), the first measurement (baseline) will be made.
Subsequently, the Swaddy® containment device will be placed and the containment will be maintained for 3 hours, in which the same variables will be measured: Heart Rate (HR), Respiratory Rate (RF), temperature, O2 Saturation (SatO2) and pain scale at 60, 120 and 180 minutes.
This procedure will be repeated on day 2 and 3. On day 4, the same measurements will be carried out using standard containment care.
This procedure will be repeated on days 5 and 6 (all three at approximately the same time of day as in the intervention).
|
In Group 1, on the first day (day 1), the first measurement (baseline) will be made.
Subsequently, the Swaddy® containment device will be placed and the containment will be maintained for 3 hours, in which the same variables will be measured: Heart Rate (HR), Respiratory Rate (RF), temperature, O2 Saturation (SatO2) and pain scale at 60, 120 and 180 minutes.
This procedure will be repeated on day 2 and 3. On day 4, the same measurements will be carried out using standard containment care.
This procedure will be repeated on days 5 and 6 (all three at approximately the same time of day as in the intervention).
|
|
Active Comparator: Group Swaddy second
In Group 2, on the first day (day 1), the first measurement (baseline) will be taken.
Subsequently, the patient will be kept in an incubator for 3 hours, in which the following variables will be measured: Heart Rate (HR), Respiratory Rate (RF), temperature, O2 Saturation (SatO2) and pain scale at 60, 120 and 180 minutes, using standard containment care.
This procedure will be repeated on day 2 and 3. On day 4, the same measurements will be carried out by applying containment with the Swaddy® device and will be repeated on days 5 and 6.
|
In Group 2, on the first day (day 1), the first measurement (baseline) will be taken.
Subsequently, the patient will be kept in an incubator for 3 hours, in which the following variables will be measured: Heart Rate (HR), Respiratory Rate (RF), temperature, O2 Saturation (SatO2) and pain scale at 60, 120 and 180 minutes, using standard containment care.
This procedure will be repeated on day 2 and 3. On day 4, the same measurements will be carried out by applying containment with the Swaddy® device and will be repeated on days 5 and 6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comfort B scale
Time Frame: three hours during the intervention
|
It is a scale validated in pediatrics that assesses the behavioral signs of the newborn.
Its maximum value is 30 and its minimum is 6.
And the higher score, is the greater the pain or stress.
|
three hours during the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart rate
Time Frame: three hours during the intervention
|
Heart rate
|
three hours during the intervention
|
|
Respiratory rate
Time Frame: three hours during the intervention
|
Respiratory rate
|
three hours during the intervention
|
|
Oxygen saturation
Time Frame: three hours during the intervention
|
Oxygen saturation
|
three hours during the intervention
|
|
Temperature
Time Frame: three hours during the intervention
|
Temperature
|
three hours during the intervention
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IIBSP-SWA-2025-35
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stress
-
Massachusetts General HospitalCompletedStress | Emotional Stress | Psychological Stress | Social Stress | Life StressUnited States
-
Center for Advanced Facial Plastic SurgeryCompletedStress | Stress, Physiological | Stress Response | Stress (Psychology) | Healthy Adult Female Participants | Stress, Psychologic | Stress Perception | Stress Levels | Stress, Psychological CumulativeUnited States
-
Amsterdam UMC, location VUmcRigshospitalet, Denmark; Universitätsklinikum Hamburg-EppendorfNot yet recruitingStress | Stress and Burnout | Stress BiomarkersGermany, Denmark
-
University of California, Los AngelesUniversity of California, San Francisco; Stanford University; California Initiative...CompletedStress | Stress, Psychological | Stress, Emotional | Stress, Physiological | Stress ReactionUnited States
-
Canterbury Christ Church UniversitySussex Partnership NHS Foundation TrustEnrolling by invitationOccupational Stress or Workplace StressUnited Kingdom
-
University of PadovaCompletedStress | Stress Disorder | Work Related StressItaly
-
Amasya UniversityCompletedThe Effect of Online Stress Management Program on Nurses' Individual Workload Perception, and StressStress | Nursing | Stress ManagementTurkey (Türkiye)
-
University of Thi-QarCompletedPsychological Stress | Academic StressIraq
-
University of North Carolina, Chapel HillWashington University School of Medicine; United States Department of Defense; University of Florida and other collaboratorsRecruitingPost-traumatic Stress Disorder | Acute Stress Disorder | Acute Stress ReactionUnited States
-
K.G. Razumovsky Moscow State University of Technologies...RecruitingStress | Stress (Psychology)Russia
Clinical Trials on Swaddy day 1, 2, 3
-
Norwegian University of Science and TechnologyCompleted
-
H. Lundbeck A/STerminatedSchizophreniaBulgaria, Czechia, Estonia, Germany, Hungary, Latvia, Poland, Ukraine
-
Verrica Pharmaceuticals Inc.Q2 Solutions; Instat Clinical Research; HeartcoR Solutions; Myonex; Vial Health Technology... and other collaboratorsCompletedCarcinoma | Skin Cancer | Basal Cell Carcinoma | Cancer of the Skin, Basal Cell | Cancer of the SkinUnited States
-
Izun Pharma LtdSuspendedGingival Inflammation in Diabetic PatientsIsrael
-
The Affiliated Hospital of Qingdao UniversityNot yet recruiting
-
Boston University Charles River CampusNot yet recruitingAging | Memory | Noninvasive Brain Stimulation
-
Nordic Bioscience A/SCompleted
-
Youssef DaaliCompleted
-
ValbiotisBiofortis Mérieux NutriSciencesCompletedDiabetes type2 | Prediabetic State | DysglycemiaItaly, France, Germany, Poland, Romania, Bulgaria, Hungary
-
Johnson & Johnson Vision Care, Inc.Completed